Featured
Novo Nordisk and Eli Lilly have proven GLP-1 drugs can deliver surgery-level weight loss - but with patients regaining much of it after stopping, the market's real value may depend on long-term adherence rather than who wins on efficacy.
Abdul Wasey Bhatti19 Jun 20265 min read
Read ArticleThoma Bravo's $5bn Medallia loss and EQT's £10.7bn Intertek acquisition tell the same story from opposite ends. Private equity's software bet has failed. The platform strategy is what comes next.
Private EquitySoftwareMergers and AcquisitionsEQTThoma Bravo
Alexander Eklund8 min read
Read ArticleMarkets19 Jun 2026
Boots looked like a deal story, but choosing a $10bn sale over a London float is really a verdict on the IPO: when a listing can't promise a price or a date, certainty wins.
Private EquityIPOsBootsLondon Stock Exchange
Abir Ghosh Biswas6 min read
Read ArticleMarkets17 Jun 2026
The proposed takeover highlights how ownership of digital platforms is becoming just as important as ownership of the content itself.
Fox CorporationRokuStreamingMergers and AcquisitionsConnected TV
Gaurav Bohra7 min read
Read ArticleAbout
The London Review is a student-led publication focused on financial markets and current events. We publish clear, data-driven analysis that bridges academic rigour with accessible writing.
Founded by students at the London School of Economics, The London Review was created to develop informed public commentary on economics, markets, and policy while giving emerging writers a serious editorial platform.
To get in contact, email us at: [email protected].
The content published on The London Review is for informational and educational purposes only and does not constitute financial, investment, or legal advice. All opinions are those of the individual author and do not reflect the editorial stance of The London Review or the views of the London School of Economics, University College London, or any affiliated institution. Readers should independently verify any facts or figures before relying on them.